Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

NCT03647163 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Non Small Cell Lung Cancer
Neuroendocrine Carcinoma
Renal Cell Carcinoma (RCC)

Interventions

BIOLOGICAL: VSV-IFNβ-NIS
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: ipilimumab + nivolumab

Sponsor

Vyriad, Inc.

Collaborators

[object Object]